Immunological Assessment of Key Biomarkers in Stage III Breast Cancer
DOI:
https://doi.org/10.22317/jcms.v10i3.1579Keywords:
Breast cancer, CTLA-4, interleukins, ROC analysisAbstract
Objective: To investigate the predictive role of some immune parameters in progressive and diagnostic of stage III breast cancer BC patient.
Methods: The study was conducted at Specialized Oncology Center – Tikrit City, and the Oncology of Baghdad Teaching Hospital, Baghdad city, Iraq, on 80 blood samples, 50 samples from women with stage III breast cancer, and 30 samples for control group (healthy women), the age range (25–50) year. The collect serum assessed by ELIZA, and the data analyzed by Independent-Samples T test spss. While AUC is measured by MedCalc.
Results: Serum levels of all parameters were dramatically higher in patients group compared to control except in IL-23 which exhibited
slight elevation statically not significant. The (AUC) for the associated ROC curve of CA15-3 (1), TGF-β (1) and IL-10 (1) were the largest.
AUC is valuable diagnostic parameters to predict of progressive and diagnostic of the disease, followed by TNF-α (0.997), IL-6 (0.974), IL-17 (0.890), IL-8 (0.838), CTL-4 (0.819) and finally the lowest on was IL-23 (0.616).
Conclusion: Increasing levels of the measured parameters are an essential predictor of progressive and diagnostic of the disease.
References
WHO. Breast Cancer. Encyclopedia of Obesity (2024). doi:10.4135/9781412963862.n63
Directorate, T. A. Republic of Iraq Ministry of Health. 1–10 (2020).
Fejzić, H., Mujagić, S., Azabagić, S. & Burina, M. Tumour marker CA 15-3 in breast cancer patients. Acta Med. Acad. 44, 39–46 (2015).
Van Coillie, S., Wiernicki, B. & Xu, J. Molecular and Cellular Functions of CTLA-4. in Advances in Experimental Medicine and Biology 1248, 7–32 (2020).
Walker, L. S. K. & Sansom, D. M. The emerging role of CTLA4 as a cellextrinsic regulator of T cell responses. Nat. Rev. Immunol. 11, 852–863 (2011).
Alshaker, H. A. & Matalka, K. Z. IFN-γ, IL-17 and TGF-β involvement in shaping the tumour microenvironment: The significance of modulating such cytokines in treating malignant solid tumours. Cancer Cell Int. 11, (2011).
Morris, R. M., Mortimer, T. O. & O’Neill, K. L. Cytokines: Can Cancer Get the Message? Cancers (Basel). 14, (2022).
Dunlop RJ, Campbell, C. Cytokines and Advanced Cancer -Journal of Pain and Symptom Management. J. Pain Symptom Manage. 20, 214–232 (2000).
Kong, K. F. et al. Protein kinase C-η controls CTLA-4-mediated regulatory T cell function. Nat. Immunol. 15, 465–472 (2014).
Greten, F. R. & Grivennikov, S. I. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity 51, 27–41 (2019).
Amin, M. N. et al. Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer. SAGE Open Med. 8, (2020).
Svobodova, S. et al. CEA, CA 15-3, and TPS as prognostic factors in the follow-up monitoring of patients after radical surgery for breast cancer. Anticancer Res. 38, 465–469 (2018).
Kern, R. & Panis, C. CTLA-4 Expression and Its Clinical Significance in Breast Cancer. Arch. Immunol. Ther. Exp. (Warsz). 69, (2021).
Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161, 205–214 (2015).
Erfani, N., Razmkhah, M. & Ghaderi, A. Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer. Cancer Invest. 28, 828–832 (2010).
Chen, X. et al. CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Oncotarget 8, 13703–13715 (2017).
Grubczak, K. et al. Differential response of mda-mb-231 and mcf-7 breast cancer cells to in vitro inhibition with ctla-4 and pd-1 through cancerimmune cells modified interactions. Cells 10, (2021).
Sasidharan Nair, V. et al. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin. Epigenetics 10, (2018).
Tu, L. et al. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumour-infiltrating immune cells and survival. Int. J. Cancer 147, 423–439 (2020).
Singh, S. R., Rameshwar, P. & Siegel, P. Targeting tumour microenvironment in cancer therapy. Cancer Lett. 380, 203–204 (2016).
Sanjabi, S., Oh, S. A. & Li, M. O. Regulation of the immune response by TGF-β: From conception to autoimmunity and infection. Cold Spring Harb. Perspect. Biol. 9, (2017).
Moses, H. & Barcellos-Hoff, M. H. TGF-β Biology in mammary development and breast cancer. Cold Spring Harb. Perspect. Biol. 3, 1–14 (2011).
Bagati, A. et al. Integrin αvβ6–TGFβ–SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer. Cancer Cell 39, 54-67.e9 (2021).
Shen, Z. et al. MicroRNA-105 is involved in TNF-α-related tumour microenvironment enhanced colorectal cancer progression article. Cell Death Dis. 8, (2017).
Raman Preet Kaur, Kanika Vasudeva, Heena Singla, R. P. S. B. Analysis of proand anti-inflammatory cytokine gene variants and serum cytokine levels as prognostic markers in breast cancer. J. Cell. Physiol. 233, 9716–9723 (2018).
Sparano, J. A. et al. Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer. npj Breast Cancer 8, (2022).
Hartman, Z. C., Poage, G. M., Den Hollander, P., Tsimelzon, A., Hill, J., Panupinthu, N., ... & Brown, P. H. (2013). Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer research, 73(11), 3470-3480.
Akdis, M. et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J. Allergy Clin. Immunol. 138, 984–1010 (2016).
John L. Langowski, Xueqing Zhang, Lingling Wu, Jeanine D. Mattson, Taiying Chen, Kathy Smith, Beth Basham, Terrill McClanahan, R. A. K. & M. O. IL-23 promotes tumour incidence and growth _ Nature. Nature 442, 461–465 (2006).
Zhang, L. et al. IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis 35, 1330–1340 (2014).
Nie, W., Yu, T., Sang, Y. & Gao, X. Tumour-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumour microenvironment. Biochem. Biophys. Res. Commun. 482, 1400–1406 (2017).
Panneerselvam, J. et al. Inflammatory mediators and gut microbial toxins drive colon tumourigenesis by il‐23 dependent mechanism. Cancers (Basel). 13, 1–19 (2021).
Hao, S. S. J. Z. J. A. X. Aberrant expression of IL-23_IL-23R in patients with breast cancer and its clinical significance. Mol. Med. Rep. 17, (2018).
Kawaguchi, K. et al. Alteration of specific cytokine expression patterns in patients with breast cancer. Sci. Rep. 9, 1–12 (2019).
Wang, H. & Yang, X. Association between serum cytokines and progression of breast cancer in Chinese population. Med. (United States) 96, 4–7 (2017).
Baumgarten, S. C. & Frasor, J. Minireview: Inflammation: An instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol. Endocrinol. 26, 360–371 (2012).
Guo, Y., Xu, F., Lu, T., Duan, Z. & Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38, 904–910 (2012).
Liu, G., Chen, X. T., Zhang, H. & Chen, X. Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients. Front. Oncol. 12, (2022).
Ohtake, T. S. M. S. K. G. Y. M. M. N. K. T. N. A. T. Prognostic impact of interleukin‑6 and C‑reactive protein on patients with breast cancer. Oncol. Lett. 17, 5139–5146 (2019).
K. Abd-Elaziz, C., A. Abd El Moneim, N., E. El Fek, S. & M. Arafat, A. Serum Y-Box Binding Protein 1 (YBX-1) and Interleukin 6 (IL-6) Are Associated with Metastasis in Breast Cancer Patients. Adv. Breast Cancer Res. 08, 119–134 (2019).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
